Literature DB >> 12580369

Emerging cancer-targeted therapies.

Robert J Arceci1, Timothy P Cripe.   

Abstract

There is reason to believe that the unfolding revolution in molecular biology and translational research will allow selective targeting of tumor cells, and radically change the way general practitioners and pediatric oncologists treat and follow children with cancer. This article highlights some of the most promising approaches being tested in the field. By learning about the underlying biology, the remaining hurdles, the projected timeline, and the possible impact of new therapies on the practice of pediatric oncology, health care professionals and patients should be better prepared for the future of pediatric oncology.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12580369     DOI: 10.1016/s0031-3955(02)00096-2

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  2 in total

Review 1.  Oncolytic virus and PD-1/PD-L1 blockade combination therapy.

Authors:  Chun-Yu Chen; Brian Hutzen; Mary F Wedekind; Timothy P Cripe
Journal:  Oncolytic Virother       Date:  2018-07-31

Review 2.  Immunotherapeutic Challenges for Pediatric Cancers.

Authors:  Brian Hutzen; Mohammed Ghonime; Joel Lee; Elaine R Mardis; Ruoning Wang; Dean A Lee; Mitchell S Cairo; Ryan D Roberts; Timothy P Cripe; Kevin A Cassady
Journal:  Mol Ther Oncolytics       Date:  2019-08-28       Impact factor: 7.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.